Francis Burrows

8.6k citations

109 papers · 6.5k indexed · 2 hit papers · h-index 39

Impact in

Molecular Biology top 1%
- Heat shock proteins research
- ATP Synthase and ATPases Research
- Angiogenesis and VEGF in Cancer
- Ubiquitin and proteasome pathways
- Cell death mechanisms and regulation
Immunology top 2%
- Toxin Mechanisms and Immunotoxins

Papers in

Hematology 19
- Acute Myeloid Leukemia Research 13
Immunology 24
- Toxin Mechanisms and Immunotoxins 17

Co-authors: Adeela Kamal Marcus F. BoehmHong ZhangLin Zhang John Sensintaffar Lawrence C. Fritz Philip E. Thorpe Neal Rosen
Journals: Cancer Research (10 papers)Blood (10 papers)Molecular Cancer Therapeutics (8 papers)Clinical Cancer Research (5 papers)Journal of Medicinal Chemistry (4 papers)
Partner nations: United States United Kingdom Spain

In The Last Decade

Francis Burrows

109 papers receiving 6.3k citations

Hit Papers

align trajectories log scale

The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins 2007 · 507 citations

Peers

Countries citing papers authored by Francis Burrows

Since Specialization

Citations

This map shows the geographic impact of Francis Burrows's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Burrows with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Burrows more than expected).

Fields of papers citing papers by Francis Burrows

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis Burrows. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Burrows. The network helps show where Francis Burrows may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Francis Burrows, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Francis Burrows Line = papers co-authored together Francis Burrows links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers Neoplasia ·Mélanie Bost-Fievet, Sankar Jagadeeshan, Aleksei P. Maslakov, Mao Zhenwei, Manu Prasad, M. Larsen, 侯征峰, Noam Erez, Jhonatan Emel Bastos Reyes, A. N. Pines, Blaire Moody Rideout, Irit Allon, Luc G.T. Morris, Gloria H. Su, Hai Wang, Ari J. Rosenberg, Linda Kessler, Francis Burrows, Moshe Elkabets	2025	1
2	Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia Blood ·直美村越, Md. Hafiz Uddin, StefanE. Schmidt, Novalita Oriza, Amro Aboukameel, Husain Yar Khan, Guangqing Yang, Jay Yang, Gregory Dyson, Steven Buck, Asfar S. Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian	2024	2
3	Abstract 1071: Tipifarnib synergizes with TKIs in clear cell renal cell carcinoma models Cancer Research ·Jovylyn Gatchalian, Linda Kessler, M. Kascha, Francis Burrows, Shivani Malik	2023	1
4	Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas Molecular Cancer Therapeutics ·Mara Gilardi, Zhiyong Wang, Marco Proietto, Anastasia Chillà, Vladimir A. Nikonov, Yusuke Goto, Marco Vanoni, Matthew R. Janes, Zbigniew Mikulski, Antonio Gualberto, Alfredo Molinolo, Napoleone Ferrara, J. Silvio Gutkind, Francis Burrows	2020	78
5	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma Scientific Reports ·P Collins James, R. Mondéjar, Nerea Martı́nez, Muḥammad T̤āhirulqādrī, Cristina Pérez, David Merino, Zhengdao Li, Anna Esteve‐Codina, Berta Fusté, Marta Gut, Francis Burrows, Catherine Scholz, José P. Vaqué, Antonio Gualberto, Miguel Á. Piris	2020	10
6	Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer Molecular Cancer Research ·Ali Toosi, Amanda Kirane, Huocong Huang, Noah Sorrelle, Francis Burrows, Michael T. Dellinger, Rolf A. Brekken	2018	15
7	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma Cancer Biology & Therapy ·Ching-Te Chou, Shannon M. Matulis, Chen Yingu, Vikas A. Gupta, Agnes Nyor, Francis Burrows, Ajay K. Nooka, Jonathan L. Kaufman, Sagar Lonial, Lawrence Boise	2016	18
8	A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer Journal of Thoracic Oncology ·Barbara J. Gitlitz, Eric Bernstein, Edgardo S. Santos, Remigiusz, Ginger L. Milne, Carl Kamme, Francis Burrows, Sara Zaknoen	2014	29
9	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor Clinical Cancer Research ·Stela Álvarez-Fernández, Elsa Rahmat Saputra, Valdés Cerda, Sara Zaknoen, Enrique M. Ocio, Jesús F. San Miguel, Francis Burrows, Azucena Esparís‐Ogando, Atanasio Pandiella	2013	43
10	BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance International Journal of Cancer ·Hong Zhang, Laura Neely, Karen Lundgren, Ighor Ramon Pallu Doro Pereira, Rachel Lough, Anderson Mojica, Francis Burrows	2009	62
11	Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor Molecular Cancer Therapeutics ·Daniel D. Von Hoff, M. Beeram, Waydande Hindurao, G. Valoppi, Januario E. Castro, Mitesh J. Borad, Francis Burrows, Denise Trone, James R. Woodworth, Shabnam Tangri, Garay Magdolna, Chris Storgard, M. W. Saif	2007	1
12	Drugging the Cancer Chaperone HSP90 Annals of the New York Academy of Sciences ·Paul Workman, Francis Burrows, Len Neckers, Neal Rosen	2007	437
13	CNF2024 - The first clinical stage synthetic oral Hsp90 inhibitor Cancer Research ·Karen Lundgren, Adeela Kamal, Rachel Lough, Anderson Mojica, John Sensintaffar, Cindy Yang, Hong Zhang, Gregg Timony, Kevin Hong, Srinivas Rao Kasibhatla, Marcus F. Boehm, Francis Burrows	2006	1
14	The effect of EC78, a novel Hsp90 inhibitor alone and in combination with radiation in head and neck squamous cell carcinoma Clinical Cancer Research ·Xiaoying Yin, Hong Zhang, Francis Burrows, Carol G. Shores	2006	1
15	The heat‐shock protein 90 inhibitor 17‐allylamino‐17‐demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis Journal of Neurochemistry ·Cinzia Dello Russo, Paul Polak, I.I. Staroverov, Alessandra Spagnolo, Anthony Sharp, Patricia Murphy, Adeela Kamal, Francis Burrows, Lawrence C. Fritz, Douglas L. Feinstein	2006	63
16	A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors Cancer Research ·Adeela Kamal, John Sensintaffar, E A Andreeva, Lin Zhang, Marcus F. Boehm, Lawrence C. Fritz, Francis Burrows	2004	28
17	Synthesis and Biological Evaluation of a New Class of Geldanamycin Derivatives as Potent Inhibitors of Hsp90 Journal of Medicinal Chemistry ·А. Саминская, Adeela Kamal, David J. Busch, K S Rholl, Lin Zhang, Gregg Timony, Annette Bigalke, Katy Trent, Rachel Lough, К.В. Федотова, Samina Y. Khan, Francis Burrows, Marcus F. Boehm	2004	68
18	A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature ·Adeela Kamal, K S Rholl, John Sensintaffar, Lin Zhang, Marcus F. Boehm, Lawrence C. Fritz, Francis Burrows Hit paper breakdown →	2003	1121
19	Aquatic millipedes in Australia: a biological enigma and a conservation saga Australian Zoologist ·Francis Burrows, Dinah Hales, Andrew J. Beattie	1994	3
20	Inhibition of germination in privet. Plant protection quarterly ·Francis Burrows, Masamichi Oba	1986	9

About Francis Burrows

Francis Burrows is a scholar working on Hematology, Immunology, Genetics, Molecular Biology and Oncology, having authored 109 papers that have together received 6.5k indexed citations. Recurring topics across this work include Heat shock proteins research (32 papers), Toxin Mechanisms and Immunotoxins (17 papers), Acute Myeloid Leukemia Research (13 papers), Protein Degradation and Inhibitors (12 papers), Chronic Lymphocytic Leukemia Research (10 papers), Computational Drug Discovery Methods (10 papers), Cancer-related Molecular Pathways (9 papers) and Lung Cancer Treatments and Mutations (9 papers). The work is most often cited by research in Molecular Biology (4.9k citations), Immunology (1.1k citations), Cell Biology (828 citations), Physical and Theoretical Chemistry (375 citations) and Oncology (1.1k citations). Francis Burrows has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Adeela Kamal, Marcus F. Boehm, Hong Zhang, Lin Zhang, John Sensintaffar, Lawrence C. Fritz, Philip E. Thorpe, Neal Rosen, Paul Workman and Len Neckers. Their work appears in journals such as Cancer Research, Blood, Molecular Cancer Therapeutics, Clinical Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact